Cancer immunotherapy candidate BSI-508, a bispecific fusion molecule targeting PD-1 and CD47, is undergoing early development at Biosion Inc., who recently presented preclinical data on the product.
IL-18 is a pro-inflammatory cytokine that triggers IFN-γ production and increases T- and NK-cell activity. IL-18’s effects are blocked by IL-18 binding protein (IL-18BP), an endogenous protein that binds to IL-18 with high affinity and that is highly present in the tumor microenvironment (TME).
Researchers from Bliss Biopharmaceutical Co. Ltd. presented the discovery and preclinical evaluation of BB-1701, a new HER2-targeting eribulin-containing antibody-drug conjugate (ADC) being developed as a potential new anticancer agent.
Human natural killer (NK) cells play an essential role in tumor surveillance and can attack malignant cells in an antigen-independent manner. Because of this, allogeneic NK cells can be engineered as off-the-shelf therapies and may be used to target different hematological malignancies or solid tumors.
Protein S-palmitoylation is a post-translational lipid modification that regulates the stability and cellular distribution of numerous cancer-related proteins. A family of 23 palmitoyl transferases, called zinc finger Asp-His-His-Cys-type (ZDHHC), mediates this lipid modification. However, the potential role of palmitoyl transferases in tumor progression and immunotherapy in pancreatic adenocarcinoma (PAAD) remains unexplored.
Around 73,000 women are diagnosed with triple-negative breast cancer (TNBC) every year in the U.S. and EU. TNBC grows and spreads faster than other types of breast cancer; moreover, it has less treatment options, and usually, a worse prognosis.
T-cell exhaustion is a differentiation state of T cells associated with tumor progression in the context of cancer. One of the co-stimulatory molecules in the tumor microenvironment, 4-1BB, triggers a signaling cascade resulting in cytokine secretion and upregulation of antiapoptotic molecules.
RSS
